Search

Background: Hereditary Pancreatitis (HP) is a rare inherited condition. We reviewed our experience over the last 20 years. Aims: The aim of our study was to evaluate the clinical course of HP in children. Patients & methods: 240 children with chronic pancreatitis, hospitalized since 1988 to 2013, were enrolled into the study. The medical records of these patients were reviewed for data on the presentation, diagnostic findings and endoscopic treatment. All children were screened for the PRSS1 gene mutations. Results: Hereditary pancreatitis was diagnosed in 31 patients (12.9%). PRSS1 gene mutations were found in 27 patients. We detected R122H/in 13, R122C/in 8, N29I/in 5 and E79K/in 1 patient. Family history was positive in 26 children with HP (84%). In 4 patients without mutations diagnosis was made when patients satisfied the requirements of the family history. In one patient we found SPINK1 mutation. In 2 children CFTR mutation was present. There was no difference in age of the disease onset between HP group and non-HP group (8 vs. 9.1 years; NS). In children with PRSS1 mutation ERCP had mean 2,5o Cambridge grade, vs. 1.6o, p

s / Pancreatology 12 (2012) 502–597 565 We present the case of a 54 year old female patient, who underwent surgery for a neuroendocrine tumor, with a large pancreatic tail mass, diagnosed by computer tomography. Laparoscopic distal resection of the pancreas was conducted. The perioperative period was complicated by an infection of the wound and suppuration. The patient was discharged on the 7th day after the operation. Postoperative histopathological examination revealed the intrapancreatic accessory spleen. Accessory spleen mimicking a pancreatic tumor is difficult to diagnose. Some papers compare examination methods, but usually they are complicated, expensive and unavailable to patients. Moreover, in most of cases, EUS-FNA is impossible due to splenic vessels. In such cases, minimal invasive procedures appear to offer a good alternative to classic operations.

s / Pancreatology Background: Previous reports that the human equilibrative nucleoside transporter (hENT1) may be predictive of improved survival following adjuvant gemcitabine treatment have largely been based on retrospective non-randomized studies or studies of chemoradiotherapy. Here the therapeutic predictability of hENT1 expression and similar markers in patients undergoing resection for pancreatic cancer is assessed using the samples collected from the adjuvant ESPAC1/3 trials. Since these trials are randomized trials, this makes the results more scientifically compelling. Methods: An extensive purification processes was applied to antibodies to hENT1, deoxycytidine kinase-1 (dck1) and concentrative nucleoside transporter-1 (CNT1). These were validated (GCLP) using siRNA knockdowns, ICC and Western blotting prior and then optimized for immunohistochemistry. Tissue Micro Arrays (TMAs) containing tumour from non-trial pancreatic cancer patients (n1⁄469) were used to determine objective scoring systems of marker expression and then applied in a blinded manner on the ESPAC TMAs (n1⁄4434). Association between the different markers was measured using correlation of staining scores and this related to treatment group and other variables. Cox regression analysis was used to relate markers to survival prognosis, both individually and collectively, also taking in to account TNM status, tumour grade, resection margin status, smoking, age, and gender as well as survival status. Results: 59% of tumour samples had some level of hENT-1 staining, but only 3.7% had membranous staining. The median (IQR) survival was 15.2 (6.3, 37.7) months for observation (n1⁄431), 22.2 (11.7, 42.7) months for 5FU (n1⁄4201) and 23.8 (13.4, 41.6) for gemcitabine (n1⁄4202). Analysis of the relationship of staining and survival will be completed by the end March 2012. Conclusions: Potential extensive use of hENT1 staining as a stratification variable in trials means that verification of data for hENT1 is urgently required. The data generated from this trial will be potentially of great clinical value resulting in wide applicability given the unbiased nature of the randomised nature of the samples and the overall quality of the study based on GCLP and REMARK standards.